Leap Therapeutics Inc ESMO 2021 DisTinGuish Study Conference Call Transcript
Good day, everyone, and welcome to the Leap Therapeutics DKN-01 Clinical Investigator Conference Call. (Operator Instructions) Please be advised that today's call is being recorded at the company's request. At this time, I'd now I'd like to turn the call over to Dr. Cynthia Sirard, Chief Medical Officer of Leap. Please begin.
Thank you, operator. Welcome, and thank you to those of you joining us today for an update on Leap Therapeutics DKN-01 development program. I'm Cynthia Sirard, and with me today are Dr. Jaffer Ajani, Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas, MD Anderson Cancer Center in Houston, Texas.
In addition, we have Dr. Samuel Klempner, who's a member of the faculty at Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts. As well, we have Douglas Onsi, the President and Chief Executive Officer at Leap.
This call is being accompanied by a slide deck. So I will ask
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |